 |
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
U.S. Centers for Disease Control and Prevention
• News Briefs
U.S. Approves New Once-a-Day AIDS Drug From Glaxo RivalJuly 3, 2003 This article is part of TheBody.com's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document. Gilead Sciences received approval from the US Food and Drug
Administration Wednesday for a new once-a-day AIDS drug, Emtriva.
Known generically as emtricitabine, Emtriva is a nucleoside
reverse transcriptase inhibitor. Gilead now hopes to combine
Emtriva with its other HIV drug, Viread, which is also taken once
a day. The company is planning a clinical trial to test such a
combination pill against Combivir, rival drug maker Glaxo's once-a-day pill combining lamivudine and AZT. But even as two separate
pills, said Gilead CFO John Milligan, Viread and Emtriva could
compete immediately against Combivir. Gilead said the wholesale
price of Emtriva would be about $250 a month.
Back to other CDC news for July 3, 2003 This article is part of TheBody.com's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document. New York Times 07.03.03; Andrew Pollack This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
|
E-Mail
Printable Single-Page
Glossary
Share
